Apogee Therapeutics (APGE) Cash from Financing Activities (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Cash from Financing Activities data on file, last reported at $411.2 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $411.2 million, up 66004.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $807.0 million (up 1685.04% YoY), and the FY2025 annual result was $396.5 million, down 19.92% from the prior year.
• Cash from Financing Activities improved to $411.2 million in Q1 2026 per APGE's latest filing, from $375.0 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $450.5 million in Q1 2024 and troughed at -$213000.0 in Q4 2023.
• A 5-year average of $137.2 million and a median of $19.7 million in 2025 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities plunged 100.13% in 2023, then jumped 66004.02% in 2026.
• A 5-year view of Cash from Financing Activities shows it stood at $158.5 million in 2022, then plunged by 100.13% to -$213000.0 in 2023, then soared by 20924.41% to $44.4 million in 2024, then surged by 745.32% to $375.0 million in 2025, then advanced by 9.66% to $411.2 million in 2026.
• Business Quant data shows APGE's Cash from Financing Activities at $411.2 million in Q1 2026, $375.0 million in Q4 2025, and $19.7 million in Q3 2025.